CURXHIGH SIGNALFINANCIAL10-Q

CURX completed its IPO on August 27, 2025, raising approximately $12.9M and transforming from a financially distressed pre-revenue company to one with substantial capital for R&D operations.

The IPO fundamentally transformed the company's financial profile, eliminating going concern issues and providing capital to accelerate multiple drug development programs across ulcerative colitis, atopic dermatitis, rheumatoid arthritis, gouty arthritis, and diabetic foot indications. However, the dramatic increase in operating cash burn to $9.6M quarterly suggests the IPO proceeds may only provide 12-18 months of runway at current spending levels.

Comparing 2025-11-17 vs 2025-09-09View on EDGAR →
FINANCIAL ANALYSIS

The IPO injection of $12.9M drove massive increases across all balance sheet metrics, with stockholders' equity surging 4,579% to $14.3M and total assets growing 1,739% to $14.5M. However, operating losses expanded nearly 5x to $1.1M and operating cash burn accelerated dramatically to $9.6M quarterly as the company aggressively ramped R&D spending on FDA-enabling studies. While the company is now well-capitalized and no longer faces going concern issues, the accelerated burn rate indicates investors should monitor cash runway closely as multiple preclinical programs advance toward IND submissions.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+4579.4%
$305K→$14.3M

Equity base grew 4579.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Operating Cash Flow
Cash Flow
-2087.8%
-$440K→-$9.6M

Operating cash flow fell 2087.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Assets
Balance Sheet
+1926.9%
$711K→$14.4M

Current assets grew 1926.9% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+1739.3%
$787K→$14.5M

Asset base grew 1739.3% — expansion through organic growth, acquisitions, or capital deployment.

Operating Income
P&L
-487.6%
-$195K→-$1.1M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-482%
-$198K→-$1.2M

Net income declined 482% — review whether driven by operations, interest costs, or non-recurring items.

Current Liabilities
Balance Sheet
+144.9%
$76K→$186K

Current liabilities surged 144.9% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
-61.4%
$482K→$186K

Liabilities reduced 61.4% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2025-11-17
PRIOR — 2025-09-09
ADDED
On August 27, 2025, the Company successfully completed its initial public offering (the IPO ) and began trading on the Nasdaq Capital Market under the ticker symbol CURX.
Following the completion of our IPO, we incurred significant research and development ( R D ) expense, totaling approximately $ 677,474 for the three months ended September 30, 2025.
These expenditures primarily related to FDA-mandated investigational new drug ( IND )-enabling studies supporting programs in ulcerative colitis, atopic dermatitis, rheumatoid arthritis, gouty arthritis, and diabetic foot.
R D activities during the period included good laboratory practice ( GLP ) toxicology and pharmacokinetic/bioanalytical studies, chemistry, manufacturing, and controls ( CMC ) work involving formulation, stability, and method validation, as well as fees to Contract Research Organizations ( CROs ) and Contract Development and Manufacturing Organizations ( CDMOs ).
The increase in R D expense compared to prior periods reflects the progression of multiple investigational programs through preclinical development toward IND submission and future clinical evaluation, consistent with the Company s development strategy following the IPO.
+7 more — sign up free →
REMOVED
On June 20, 2024, in connection with its initial public offering (the IPO ), the Company filed a Form S-1 Registration Statement with the Securities and Exchange Commission (SEC), which was declared effective on August 12, 2025.
On August 27, 2025, the Company closed the IPO of 3,750,000 shares of common stock at the initial public offering price of $ 4.00 per share.
The net proceeds to the Company from the IPO, after deducting the underwriting discount, the underwriters fees and expenses and the offering expenses, were approximately $ 12,871,280 .
The Company s common stock is trading on the Nasdaq Capital Market under the symbol CURX.
11 There can be no assurance that the Company will achieve its business plan, raise additional capital, or secure the necessary financing to implement its current operating plan.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →